



ORIGINAL ARTICLE

Alpha1-antitrypsin deficiency in Greece: Focus on rare variants



S.A. Papiris^{a,*}, M. Veith^b, A.I. Papaioannou^a, V. Apollonatu^a, I. Ferrarotti^c, S. Ottaviani^c, A. Tzouvelekis^d, V. Tzilas^e, N. Rovina^f, G. Stratakos^g, I. Gerogianni^h, Z. Daniil^h, L. Kolilekasⁱ, K. Dimakou^e, G. Pitsidianakis^j, N. Tzanakis^j, S. Tryfon^k, F. Fragopoulos^l, E.M. Antonogiannaki^m, A. Lazaratou^a, E. Foukaⁿ, D. Papakostaⁿ, P. Emmanouil^o, N. Anagnostopoulos^g, T. Karampitsakos^d, K. Vlami^a, M. Kallieri^a, P. Lyberopoulos^a, S. Loukides^a, D. Bouros^{p,q}, A. Bush^r, M. Balduyck^s, C. Lombard^t, V. Cottin^u, J.F. Mornex^u, C.F. Vogelmeier^{b,*}, T. Greulich^{b,*}, E.D. Manali^{a,*}

^a 2nd Pulmonary Medicine Department, Medical School, General University Hospital “Attikon”, National and Kapodistrian University of Athens, Greece 1 Rimini Street, Haidari 12462, Greece

^b Department of Medicine, Pulmonary and Critical Care Medicine, Member of the German Center for Lung Research (DZL), UKGM, Marburg, Germany

^c Center for Diagnosis of Inherited Alpha1-antitrypsin Deficiency, Department of Internal Medicine and Therapeutics, Pneumology Unit, Fondazione IRCCS Policlinico San Matteo, Università di Pavia, Pavia, Italy

^d Department of Respiratory Medicine, General Hospital of Patras, University of Patras, Greece

^e 5th Pulmonary Department, Athens Chest Hospital “Sotiria”, Athens Greece

^f 1st Department of Pulmonary Medicine and Intensive Care Unit, Medical School, National and Kapodistrian University of Athens, Athens 115 27, Greece

^g 1st Respiratory Medicine Department of the National, Kapodistrian University of Athens, Athens, Greece

^h Department of Respiratory Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa Greece

ⁱ 7th Pulmonary Department, Athens Chest Hospital “Sotiria”, Athens Greece

^j Department of Thoracic Medicine, University Hospital, University of Crete, Heraklion, Crete 71110, Greece

^k General Hospital “G. Papanikolaou”, Thessaloniki, Greece

^l Pulmonary Department, General Hospital of Nicosia, Cyprus

^m 4th Pulmonary Department, Athens Chest Hospital “Sotiria”, Athens Greece

ⁿ A Department of Pulmonary Medicine, Aristotle University of Thessaloniki, “G. Papanikolaou” Hospital, Exochi, Thessaloniki, Greece

^o Mediterraneo Hospital, Glyfada, Greece

^p Iatriko Medical Center, Athens, Greece

^q School of Medicine, National and Kapodistrian University of Athens, Athens Greece

^r Paediatrics and Paediatric Respiriology, Imperial College, Imperial Centre for Paediatrics and Child Health, Royal Brompton Harefield NHS Foundation Trust, London, United Kingdom

Abbreviations: A1antitrypsin, (AAT); AAT deficiency, (AATD); dried blood spot, (DBS); diffusing capacity for carbon monoxide, (DLCO); forced expiratory volume in 1 second, (FEV₁); Forced mid-expiratory flow, (FEF_{25–75%}); Forced vital capacity, (FVC); isoelectric focusing, (IEF); polymerase chain reaction, (PCR).

* Corresponding authors.

E-mail address: papiris@otenet.gr (S.A. Papiris).

Professor S.A. Papiris and Dr M.Veith contributed equally to this work as first authors and Professor C.F. Vogelmeier, T. Greulich and E.D. Manali contributed equally as senior authors.

<https://doi.org/10.1016/j.pulmoe.2022.12.007>

2531-0437/© 2023 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

^s *laboratoire de Biochimie et Biologie Moléculaire (HMNO), Centre de Biologie Pathologie, Faculté de pharmacie et EA 7364 RADEME, Laboratoire de Biochimie et Biologie Moléculaire, CHU de Lille, Université de Lille, Lille, France*

^t *Laboratoire d'Immunologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon and Université Claude Bernard-Lyon 1, Lyon, France*

^u *Service de pneumologie, Centre National Coordinateur de Référence des Maladies Pulmonaires Rares, Hôpital Louis Pradel, Hospices Civils de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, UMR754 INRA, IVPC, Lyon, France*

Received 8 August 2022; accepted 7 December 2022

Available online 14 February 2023

KEYWORDS

A₁antitrypsin;
Rare variants;
Emphysema;
Genetic diversity;
Gene sequencing;
Greeks

Abstract

Purpose: A₁Antitrypsin deficiency (AATD) pathogenic mutations are expanding beyond the PI*Z and PI*S to a multitude of rare variants.

Aim: to investigate genotype and clinical profile of Greeks with AATD.

Methods: Symptomatic adult-patients with early-emphysema defined by fixed airway obstruction and computerized-tomography scan and lower than normal serum AAT levels were enrolled from reference centers all over Greece. Samples were analyzed in the AAT Laboratory, University of Marburg-Germany.

Results: Included are 45 adults, 38 homozygous or compound heterozygous for pathogenic variants and 7 heterozygous. Homozygous were 57.9% male, 65.8% ever-smokers, median (IQR) age 49.0(42.5–58.5) years, AAT-levels 0.20(0.08–0.26) g/L, FEV₁(%predicted) 41.5(28.8–64.5). PI*Z, PI*Q0, and rare deficient allele's frequency was 51.3%, 32.9%, 15.8%, respectively. PI*ZZ genotype was 36.8%, PI*Q0Q0 21.1%, PI*MdeficientMdeficient 7.9%, PI*ZQ0 18.4%, PI*Q0Mdeficient 5.3% and PI*Zrare-deficient 10.5%. Genotyping by Luminex detected: p.(Pro393Leu) associated with M_{Heerlen} (M1Ala/M1Val); p.(Leu65Pro) with M_{Procida}; p.(Lys241Ter) with Q0_{Bellingham}; p.(Leu377Phefs*24) with Q0_{Mattawa} (M1Val) and Q0_{Ourem} (M3); p.(Phe76del) with M_{Malton} (M2), M_{Palermo} (M1Val), M_{Nichinan} (V) and Q0_{LaPalma} (S); p.(Asp280Val) with P_{Lowell} (M1Val); P_{Duarte} (M4), Y_{Barcelona} (p.Pro39His). Gene-sequencing (46.7%) detected Q0_{GraniteFalls}, Q0_{Saint-Etienne}, Q0_{Amersfoort} (M1Ala), M_{Würzburg}, N_{Hartfordcity} and one novel-variant (c.1A>G) named Q0_{Attikon}. Heterozygous included PI*MQ0_{Amersfoort}(M1Ala), PI*MM_{Procida}, PI*Mp.(Asp280Val), PI*MO_{Feyzin}. AAT-levels were significantly different between genotypes ($p = 0.002$).

Conclusion: Genotyping AATD in Greece, a multiplicity of rare variants and a diversity of rare combinations, including unique ones were observed in two thirds of patients, expanding knowledge regarding European geographical trend in rare variants. Gene sequencing was necessary for genetic diagnosis. In the future the detection of rare genotypes may add to personalize preventive and therapeutic measures.

© 2023 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

A₁Antitrypsin (AAT) which is mainly produced by hepatocytes, acts as major protease inhibitor in the serum and targets preferentially excessive human neutrophil elastase.¹ Normally its plasma levels range from 0.9 g/L to 2 g/L in the absence of an acute phase response. AAT deficiency (AATD) is characterized by a significant decrease of AAT plasma levels usually below the “protective level” of 0.57 g/L.^{2,3} Low or absent plasma levels and/or dysfunctional AAT molecules increase risk to develop pulmonary emphysema, less commonly liver disease and rarely other systemic manifestations.^{4–7} Cigarette smoking or equivalent is considered the major additional risk factor in these patients.^{1,2} AATD is one of most common Mendelian disorders and PI*Z and PI*S variants account for the majority of cases worldwide.^{8,9} However, the genetic repertoire of AATD pathogenic mutations is constantly expanding far beyond the PI*Z and PI*S

variants to a multitude of rare alleles such as the deficient or dysfunctional ones leading to the production of misfolded AAT protein such as the M, N, P, O deficient and the null (Q0) variants without any production of AAT protein.^{10,11} The prevalence of rare genotypes other than PI*ZZ and PI*SZ recorded so far ranges from 1.1% in countries like France to 20.4% in countries like Italy.^{12–16} Their epidemiology and geographic distribution, pathogenetic role and clinical expression need further investigation. This study aimed to investigate for the first ever time in Greece genotype and clinical profile characteristics of AAT deficiency patients.

Patients and methods

In this retrospective collaborative Greek study, we assessed the genotype and clinical profile of AAT deficiency patients followed-up in 12 hospital centers all over Greece a country

of 10.400.000 people [https://www.statistics.gr/press-kit_census_results_2021] in an effort to capture the entire population. For that purpose, after authorization by the Medical Ethics Committee of General University Hospital “Attikon”, Athens, Greece, a questionnaire was addressed to all Tertiary University Hospitals as well as Referral Centers of the National Health System (NHS) and dedicated private clinics to enroll symptomatic adult patients with early emphysema defined by fixed airway obstruction and computerized tomography scan findings and lower than normal serum AAT levels documented by two consecutive measurements in the absence of an acute reaction condition verified by normal CRP levels. The overlap presence of bronchiectasis, bronchial asthma and liver disease was also reported in addition to routinely collected epidemiologic, clinical and functional data. This case-finding program is still ongoing. The data of the present study correspond to the time period from September 2018 to October 2021. Normal serum AAT levels were considered at 0.9–2 g/L by nephelometry by local laboratory standards. Following genetic results, analysis considers adults as homozygous or compound heterozygous for pathogenic variants. All adult patients included in the study fulfilled the criteria of the European Respiratory Society for the diagnosis and treatment of pulmonary disease in AATD.³ The AATD genetic analysis was performed at the German AAT Laboratory at the University of Marburg (MV, CFV, TG). For that analysis dried blood spot (DBS) samples were tested using the Progenika AAT genotyping kit (Progenika Biopharma, S, A, Derio, Spain) which can simultaneously identify and genotype 14 deficiency variants of the SERPINA1 gene based on Luminex xMAP-Technology (Luminex, Austin, TX, USA). For samples in which we suspected the presence of other mutations, due to low serum AAT levels, isoelectric focusing (IEF) was performed.^{17,18} If the results from Luminex technology and IEF tests did not correlate or an indication of a rare mutation existed, gene sequencing (Next Generation Sequencing) was done. For sequencing the DBS samples were shipped to a reference laboratory [Progenika Biopharma, Spain]. We have described the laboratory methods in detail elsewhere.¹⁷ Epidemiological, clinical, laboratory and functional data were collected in a standardized manner. Death data were recorded until October 2021, except for cases lost to follow-up. Rare and ultra-rare mutations were discussed systematically with experts from the German AAT Laboratory at the University of Marburg (MV, CFV, TG) in collaboration, when necessary, with the expert Center for Diagnosis of Inherited Alpha1-antitrypsin Deficiency at the University of Pavia on web meetings (IF, SO). Selected patients were discussed monthly in a web-based multidisciplinary meeting dedicated to AATD (www.respifil.fr) for consultation (MB, CL, VC, JFM). All patients signed written informed consent and the study was approved by the Medical Ethics Committee of General University Hospital “Attikon”, Athens, Greece (EBΔ 633/24–09–2018).

Statistical analysis

Normality of the distributions was checked with Kolmogorov-Smirnov test. Categorical variables are presented as n (%), whereas numerical variables are presented as median (interquartile ranges) since the distribution of data was skewed.

Comparisons between AAT levels in the different groups were performed using Kruskal Wallis test. Statistical significance was established at the level of $p \leq 0.05$. Data were analyzed using SPSS 17.0 for Windows (SPSS Inc., Chicago, IL, USA) and graphs were created using Graph Pad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA).

Results

Included are 45 adults, 38 homozygous or compound heterozygous for pathogenic variants and 7 heterozygous. The former was 57.9% male, 65.8% ever-smokers, diagnosed at a median age (IQR) of 49.0 (42.5–58.5) years, AAT levels of 0.20(0.08–0.26) g/L, FEV₁(% predicted), FEV₁/FVC%, FEF_{25–75} and DLCO (% predicted) of 41.5 (28.8–64.5), 49.6 (38.2–61.1), 14 (9.6–28.5) and 45.8 (31.7–58.3), respectively. Overall, 26.3% of patients presented overlapping emphysema and bronchiectasis and 2.6% bronchial asthma. Only 2.6% presented with liver disease. All patients were treated with a combination of LABA/LAMA bronchodilators in the addition of inhaled corticosteroids in 50%. Augmentation therapy was provided in 26 (68.4%) patients although 30 of them (78.9%) fulfilled all 3 criteria for treatment (age <70 years old, FEV₁ < 70% and AAT levels less than 0.57 g/L).¹⁹ No vasculitis was reported in the present cohort analysis. PI*Z, PI*Q0, PI*Mdeficient and PI*N allele’s frequency was 51.3%, 32.9%, 14.5% and 1.31%, respectively. PI*ZZ genotype was found in 36.8% of patients, PI*Q0Q0 in 21.1%, PI*MdeficientMdeficient in 7.9%, PI*ZQ0 in 18.4%, PI*Q0Mdeficient in 5.3% and PI*Zrare-deficient in 10.5% (Table 1, Fig. 1).

Distribution of patients all over Greece and in Cyprus is shown in Fig. 2. Using genotyping by Luminex the following mutations were detected: p.(Pro393Leu) which is associated with M_{Heerlen} (M1Ala/M1Val); p.(Leu65Pro) which is associated with M_{Procida}; p.(Lys241Ter) which is associated with Q0_{Bellingham}; p.(Leu377Phefs*24) which is associated with Q0_{Mattawa} (M1 Val) and Q0_{Ourem} (M3); p.(Phe76del) which is associated with M_{Malton} (M2), M_{Palermo} (M1Val), M_{Nichinan} (V) and Q0_{LaPalma} (S); p.(Asp280Val) which is associated with P_{Lowell} (M1Val); P_{Duarte} (M4), Y_{Barcelona} (p.Pro39His) (Table 2). However, this method does not detect the background, as is the case with sequencing. Therefore, in the following text the mutations are written as follows:

M_{Heerlen} (M1Ala/M1Val) = p.(Pro393Leu), Q0_{Mattawa} (M1 Val)/Q0_{Ourem} (M3) = p.(Leu377Phefs*24), M_{Malton} (M2)/M_{Palermo} (M1Val)/M_{Nichinan} (V)/Q0_{LaPalma} (S) = p.(Phe76del), P_{Lowell} (M1Val); P_{Duarte} (M4), Y_{Barcelona} (p.Pro39His) = p.(Asp280Val).⁸

Gene-sequencing in 46.7% of patients detected Q0_{GraniteFalls}, Q0_{Saint-Etienne}, Q0_{Amersfoort} (M1Ala), M_{Würzburg}, N_{Hartfordcity} and one novel-variant (c.1A>G) named Q0_{Attikon}. This mutation has never been described before; it relates to the codon of initiation of translation of the gene completely inhibiting AAT production. The variant was characterized as a null variant. A new name is planned in a separate paper (Table 2). Investigation of the study population by genotyping and next-generation sequencing approaches revealed that 24 out of 38 homozygous or compound heterozygous adult patients (63.2%) presented a multiplicity of rare variants and a diversity of rare combinations. PI*Q0_{GraniteFalls}Q0_{GraniteFalls} was encountered in 4 patients and PI*Q0_{Amersfoort}

Table 1 Epidemiological, clinical and laboratory data of adults homozygous or compound heterozygous for pathogenic variants.

Parameter	All (n = 38)	PI*ZZ (n = 14)	PI*QOQO (n = 8)	PI*Mdeficient /Mdeficient (n = 3)	PI*ZQO (n = 7)	PI*QO/Mdeficient (n = 2)	PI*Z/rare-deficient (n = 4)
Gender (Male, n (%))	22.0 (57.9)	7.0 (50.0)	4.0 (50.0)	2.0 (66.7)	5.0 (71.4)	1.0 (50.0)	3.0 (75.0)
Age at diagnosis, years	49.0 (42.5–58.5)	46.5 (42.0–64.0)	47.0 (34.0–52.0)	49.0 (37.0–49.0)	50.0 (47.0–54.0)	46.5 (26.0–46.5)	61.0 (44.0–61.0)
Ever smoker, n (%)	25.0 (65.8)	10.0 (71.4)	5.0 (62.5)	2.0 (66.7)	4.0 (57.1)	1.0 (50.0)	3.0 (75.0)
Pack-years (n)	20.0 (0.0–25.0)	20.0 (2.5–22.5)	12.5 (0.0–20.0)	9.0 (0.0–9.0)	22.5 (0.0–40.0)	10.0 (0.0–10.0)	20.0 (12.0–20.0)
A ₁ Antitrypsin level (g/L)	0.20 (0.08–0.30)	0.25 (0.20–0.30)	0.04 (0.01–0.05)	0.13 (0.04–0.13)	0.20 (0.14–0.24)	0.16 (0.07–0.16)	0.33 (0.20–0.48)
Survival 12 months, n (%)	34.0 (89.5)	12.0 (85.7)	7.0 (87.5)	3.0 (100.0)	7.0 (100.0)	2.0 (100.0)	2.0 (66.7)
Augmentation therapy, n (%)	26.0 (68.4)	11.0 (78.6)	5.0 (62.5)	2.0 (66.7)	7.0 (100.0)	2.0 (100.0)	1.0 (33.3)
All 3 criteria, n (%)	30.0 (78.9)	10.0 (71.4)	8.0 (100.0)	2.0 (66.7)	6.0 (85.7)	1.0 (50.0)	3.0 (75.0)
FEV ₁ % predicted	41.5 (28.8–64.5)	46.0 (32.0–78.5)	33.9 (28.0–72.0)	35.0 (21.0–35.0)	37.5 (21.0–41.0)	72.9 (50.0–72.9)	57.0 (47.0–57.0)
FVC% predicted	80.5 (54.6–102.3)	92.1 (64.5–101.1)	75.0 (48.0–102.0)	75.0 (54.0–75.0)	43.0 (34.0–63.4)	112.8 (106.6–112.8)	103.0 (81.0–103.0)
FEV ₁ / FVC%	49.6 (38.2–61.1)	46.5 (37.4–59.2)	48.6 (47.0–60.4)	52.0 (36.0–52.0)	51.0 (46.0–71.0)	54.8 (32.0–54.8)	57.7 (35.6–57.7)
FEF _{25–75} % predicted	14.0 (9.6–28.5)	15.5 (11.6–28.3)	9.0 (7.9–27.0)	30.0 (30.0–30.0)	14.0 (8.4–16.0)	38.7 (14.0–38.7)	25.0 (14.0–25.0)
DLCO% predicted	45.8 (31.7–58.3)	58.8 (31.7–88.5)	41.5 (30.2–47.5)	32.0 (32.0–32.0)	40.3 (27.9–61.4)	68.3 (55–68.3)	47.0 (42.0–47.0)
Bronchiectasis, n (%)	10.0 (26.3)	4.0 (28.6)	2.0 (25.0)	0.0	3.0 (42.9)	0.0	1.0 (25.0)
Bronchial asthma, n (%)	1.0 (2.6)	0.0	0.0	0.0	1.0 (14.3)	0.0	0.0
Liver disease, n (%)	1.0 (2.6)	1.0 (7.1)	0.0	0.0	0.0	0.0	0.0

Values are presented as median (IQR) unless otherwise indicated; IQR= interquartile range; p-values <0.05 were considered statistically significant, M=male; COPD= chronic obstructive pulmonary diseases; FEV₁= Forced expiratory volume in one second FVC= forced vital capacity; FEF_{25–50}= forced expiratory flow at 25–75% of forced vital capacity or forced mid-expiratory flow; DLCO= diffusing capacity of the lung for carbon monoxide; all 3 criteria: age <70 years old, FEV₁ < 70% and AAT levels less than 0.57 g/L.




Figure 1 Pie chart displaying the proportions of different genotype groups in the cohort of 38 adult Greek patients with AATD homozygous or compound heterozygous for pathogenic variants.

(M1Ala)Q0_{Amersfoort}(M1Ala) in 2, the rest of the ultra-rare combinations being represented singularly. Exceptional combinations included PI*Q0_{Amersfoort}(M1Ala)P.(Leu377Phefs*24), (a unique one), p.(Phe76del p.(Leu377Phefs*24), and p.(Leu65-Pro)p.(Pro393Leu). Genetic analysis of heterozygous patients showed 4 PI*MQ0_{Amersfoort}(M1Ala), 1 PI*MM_{Procida}, 1 PI*Mp.(Asp280Val) and 1 PI*MO_{Feyzin}. Five patients were female and three ever-smokers. Age at diagnosis had a range (minimum-maximum) of 42 (34–76) years, AAT levels of 0.16 (0.62–0.78) g/L and FEV₁% predicted of 64 (40–104)% (Table 3). Consanguinity was reported only once in an index-case PI*Q0_{Granitefalls}Q0_{Granitefalls} patient where both parents were second cousins. AAT levels were significantly different between genotypes ($p = 0.002$) with PI*Q0Q0 presenting the lowest levels (Fig. 3).

Discussion

The present study expands knowledge about the geographical distribution of genotype variants in AATD in Europe. In Greece PI*ZZ genotype was found in only 36.8% of patients while in the rest a multiplicity of rare variants and a diversity of rare combinations, including some unique ones were observed, confirming an established South-North European geographical trend in rare variants.^{7,20,21} Rare variants observed in 63.2% of patients embraced the null variants PI*Q0_{Bellingham}, PI*Q0_{Amersfoort}, PI*Q0_{Granite Falls}, PI*Q0_{Saint-Etienne}, PI*Q0_{Mattawa} and the novel PI*Q0_{Attikon} (c.1A>G) allele; and the deficient variants PI*M_{Heerlen}, PI*M_{Procida}, PI*M_{Malton}, PI*M_{Würzburg}, and PI*N_{Hardfordcity}. All genotypes included in the study proved pathogenic since they were clinically encountered in patients with early emphysema and lower than normal AAT levels. To define genotypes 46.7% of patients required gene sequencing. PI*Q0Q0 genotype was associated with the lowest AAT serum levels.

Historically, among patients with severe AATD, the PI*ZZ genotype appeared to predominate almost exclusively (98%) in Northern Europe and in Caucasians of European descent living in the USA. A smaller although significant number of homozygous PI*ZZ patients are also found in Canada, Australia, New Zealand and some countries of South America. However, more recent studies in Europe have discovered wide geographical differences, where Northern Europe, the Iberian Peninsula and Ireland present the highest prevalence

of PI*ZZ genotype, Southern and Eastern Europe the lower ones and Great Britain intermediate prevalence.^{20,21} In more detail and based on recent epidemiological evidence, the PI*ZZ genotype mean prevalence is 4.5 to 10 times higher in Denmark compared to countries like Serbia and North Macedonia, whereas data were completely lacking for Greece.^{20,21}

The present study by demonstrating that in Greece only one third of patients with early emphysema and severe AATD presented the PI*ZZ genotype confirms for the first time, to the best of our knowledge in Greece, the already established North-South European geographical trend in PI*Z variant. Many theories have been developed so far to explain this observation including the Scandinavian origin of the PI*Z allele and the association of its dispersal to the Viking migration history. Updated knowledge of human genetic diversity tends to explain the observed gradients in prevalence through another perspective, the one of “South-North cline of genetic diversity”.⁸ Differences might result from population movements the Neolithic times from the Southern European populations historically larger and genetically more diverse to the Northern ones.^{22,23}

The present study also expands knowledge about the geographical distribution of genotype variants in AATD in Europe by discovering in Greece a multiplicity of rare variants including six null variants (one novel one) and six rare deficiency ones in an exceptional diversity of rare combinations both homozygous and compound heterozygous rarely described before in one cohort. Interestingly the PI*S allele and the PI*SZ genotype considered as the second most prevalent ones worldwide were not represented in our study population.²⁴ This could be partly explained by the fact that the threshold of AAT serum levels used to select affected cases could not “capture” some of those patients and that only a fraction of PI*SZ (smokers) shows respiratory symptoms and emphysema.²⁴ In the Spanish registry of 469 patients with AATD, only 3.4% were carriers of rare variants in homozygous or compound heterozygous state.¹² In the Italian registry of 422 adult subjects with severe AATD, 20.4% of patients were found with one rare deficient/null allele in combination with an PI*S or PI*Z allele or with rare deficient/null alleles, the highest so far recorded prevalence in national registries and the closest one to our findings.¹³ In the US AATD registry of 1129 subjects, 97% of them were PI*ZZ and only 1.8% presented rare variants such as PI*Q0_{GraniteFalls}, PI*Q0_{Bellingham}, PI*M_{Malton}, PI*M_{Heerleen} and PI*P_{Lowell}.¹⁴ In the German registry of 548 individuals, 8.5% of patients were carriers of rare variants.¹⁵ Finally, in the French cohort of 312 patients, only 3 patients (1.1%) were found to carry a PI*Q0/Z genotype, whereas 84.6% were PI*ZZ and 5.5% PI*SZ.¹⁶ The comparison of our study with others in Europe and the USA delineates the singularity of our findings showing 63.2% of AATD patients with rare, ultra-rare and almost unique variants and raises fascinating questions about migration patterns and adaptation procedures that could explain such a genetic diversity in a small but historical land of Eastern Europe, Greece. The fact that rare alleles almost segregated in a restricted geographical area, are also observed sporadically in different geographic populations both European and American provides evidence of their ancestry.^{25–39} In the present cohort, the identification of null, rare-deficiency as well as a novel null variant was possible thanks to DNA-

Table 2 Biological characteristics of the alleles of the study population.

SERPINA1 mutation	Marker ID	Allele name (Molecular Background)	DNA Sequence	Intron/Exon	Mechanism	Mutation effect on the protein	Refs.
p.(Thr62Cys)		O _{Feyzin}	c.185A>G	Exon 4	Missense mutation	unknown	http://www.a1at-variantdatabase.com/detail-page-display-260.html
p.(Leu65Pro)	rs28931569	M _{Procida}	c.194T>C	Exon 2	Missense mutation	Protein deficiency	28
p.(Phe76del)	rs775982338	M _{Malton} (M2) M _{Palermo} (M1 Val) M _{Nichinan} (V) Q _{Ia palma} (S) P _{Lowell} (M1Val) P _{Duarte} (M4) Y _{Barcelona} (p.Pro39His)	c.227_229delTCTdel	Exon 2	In-frame-deletion Single amino acid deletion at position 76	Protein deficiency	30,36–38
p.(Asp280Val)	rs121912714	Q _{La palma} (S) P _{Lowell} (M1Val) P _{Duarte} (M4) Y _{Barcelona} (p.Pro39His)	c.839A>T	Exon 5	Missense mutation	Protein deficiency	8
p.(Tyr184Ter)	rs199422210	Q _{Amersfoort} (M1Ala) Q _{Bredevoor} (Unknown)	c.552C>G	Exon 2	Nonsense mutation This sequence change creates a premature translational stop signal (p.Tyr184Ter) in the SERPINA1 gene. It is expected to result in an absent or disrupted protein product	Protein absence	8,27
p.(Tyr184Ter)	rs267606950	Q _{Granite Falls}	c.552del	Exon 2	Frameshift mutation This frameshift results in a premature stop signal (p.Tyr184Ter) in the SERPINA1 gene. It is expected to result in an absent or disrupted protein product	Protein absence	29
p.(Lys187Ter)		Q _{Saint-Etienne}	c.559A>T	Exon 2	Nonsense mutation This sequence change creates a premature translational stop signal (p.Lys187Ter) in the SERPINA1 gene. It is expected to result in an absent or disrupted protein product.	Protein absence	26
p.(Lys241Ter)	rs199422211	Q _{Bellingham}	c.721A>T	Exon 3	Nonsense mutation This sequence change creates a premature translational stop signal (p.Lys241Ter) in the SERPINA1 gene. It is expected to result in an absent or disrupted protein product.	Protein absence	31
p.(Thr292Ile)	rs745624643	N _{Hartford City}	c.875C>T	Exon 5	Missense mutation	Protein deficiency	32
p.(Leu377Phefs*24)	rs763023697	Q _{Mattawa} (M1 Val) Q _{Ourem} (M3)	c.1130dup	Exon 5	Frameshift mutation An insertion of 1 nucleotide at position 353 of the protein resulted in a premature stop codon of 24 amino acids downstream. It is expected to result in an absent or disrupted protein product.	Protein absence	33,39
p.(Pro393Ser)	rs61761869	M _{Würzburg}	c.1177C>T	Exon 5	Missense mutation	Protein deficiency	34
p.(Pro393Leu)	rs199422209	M _{Heerlen**} (M1 Ala) M _{Heerlen**} (M1 Val)	c.1178C>T	Exon 5	Missense mutation	Protein deficiency	35
p.Met1?	rs1057516555	c.1A>GQ _{Attikon}	c.1A>G	Exon 4	Missense mutation	unknown	it will be fully characterized in a next paper.

* Genetic background: M1: p.(Val237Ala), M2: p.(Arg125His), M3. p.(Glu400Asp).

** MHeerlen might be considered also a null allele given its extreme low levels in serum, however in the present study it was included in the group of Mdeficient variants.




Figure 2 Distribution of the 38 patients depicted as stars of different colors in their area of origin on the map of Greece and Cyprus. Blue stars correspond to PI*ZZ patients, red stars to any combination homozygous or compound heterozygous including PI*Q0 or/and rare-deficient variants and green stars correspond to the combination of PI* Z with any PI*Q0 or rare-deficient variant.

sequencing technology which was the only one compared to IEF and PCR techniques that provided an accurate and unambiguous genotyping final result.

The sequencing protocol includes the seven exons of SERPINA1 gene (NM_001127701.1): 3 first exons corresponding to 5' UTR region and the 4 coding exons. Full exons plus intronic sequences around exon (at least 30 bp intron sequences around exons) are amplified and sequenced by Next Generation Sequencing (MiSeq, Illumina).^{17,40} This is in accordance with the recent literature which is increasingly highlighting the importance of whole SERPINA1 gene next-generation sequencing to explain new mechanisms of AATD pathophysiology in a personalized medicine era.^{41,42}

The clinical profile of our patients corresponded to the already described one of early emphysema even in the absence of smoke exposure.⁴³ In addition to PI*Z, null and rare-deficiency variants are considered factors increasing

the risk for the development of early lung disease.^{2,44,45} Pathogenicity is attributed to lower-than-normal AAT levels leading to unopposed proteolytic activity (loss of function) but also to stimulation of endoplasmic reticulum stress and inflammation pathways related to polymerization of misfolded proteins especially in some of the Mdeficient variants whose biologic and molecular behavior resembles that of PI*Z deficient ones (gain of function).⁴⁶

The fact that our study also discovered rare variants in a small number of symptomatic early emphysema patients found to be heterozygous only for rare variants such as PI*Q0_{Amersfoort} (M1Ala) in four patients and PI*M_{Procida}, p.(Asp280Val) and PI*O_{Feyzin} further confirms our findings showing the predominance of rare variants in the Greek population. In the literature there is very little data about heterozygotes showing that PI*MZ individuals are at increased risk to develop early disease and that PI*MQ0 subjects may present with emphysema, asthma or

Table 3 Clinical and molecular characteristics of adult patients heterozygous for pathogenic variants.

Patient #	gender	Age at diagnosis, years	Clinical profile	FEV ₁ % predicted	Smoking status	AAT levels (g/L)	Genotype
1	M	76.0	E, B	40.0	Ex	0.67	PI*MQ0 _{Amersfoort} (M1Ala)
2	F	53.0	B	75.0	Ex	0.78	PI*MQ0 _{Amersfoort} (M1Ala)
3	F	44.0	BA	101.0	No	0.62	PI*MQ0 _{Amersfoort} (M1Ala)
4	F	42.0	BA	98.0	No	0.72	PI*MM _{Procida}
5	M	34.0	B	75.0	No	0.70	PI*MQ0 _{Amersfoort} (M1Ala)
6	F	58.0	BA	84.0	Ex	0.63	PI*MO _{Feyzin}
7	F	55.0	E	104.0	No	0.66	PI*Mp.(Asp280Val)

M=Male, F=Female, E=Emphysema, B=Bronchiectasis, BA=Bronchial asthma, FEV₁= Forced expiratory volume in one second, A₁AT=A₁-anti-trypsin, age at diagnosis (years), Ex=ex-smoker.




Figure 3 Serum A₁ antitrypsin (AAT) levels in g/L for 38 homozygous or compound heterozygous for pathogenic variants Greek patients with early emphysema and AAT deficiency. Horizontal bars correspond to the median value (interquartile range) for each group based on the genetic analysis. The dashed line corresponds to the protective level of 0.57 g/L.

chronic bronchitis over 45 years of age, irrespective of their smoking habit.^{47–49}

The major limitation of our study is that it could be subject to selection or reporting bias and thus underscore the scale of AATD in Greece. Based on international epidemiological data,¹ the estimated number of cases in Greece approaches approximately 2500. Given the high under-recognition rate reported worldwide at 0.35 to 4%¹ the clinically identified patients should range from 9 to 100. Considering that the populations of Spain, Italy, the USA, Germany and France are 5, 6, 33.2, 8.3 and 6.7 times greater, respectively compared to Greece, the number of 45 patients included in the study may be regarded as very comparable to the “registry-based” cohorts of the countries cited-above.^{12–16} Indeed in the epidemiologic study of de Serres and Blanco the authors estimate a number of 43 PI*ZZ for Greece.⁵⁰ We consider that this calculation could be imprecise for the Greek population. The authors of the epidemiologic study themselves comment on the potential important limitations and bias of their calculations based on the methods of selection of the cohorts and on the fact that the analysis had not taken into consideration rare variants given the paucity of data. In fact, many AATD patients in Greece were considered by their treating physicians to be “PI*ZZ” without documentation before a specific and detailed evaluation of pathogenic variants was performed with the contribution of the expert laboratory of the University of Marburg in collaboration with another 3 expert centers in Europe for the Greek patients in the present study.

Conclusion

Genotyping AATD in Greece, a multiplicity of rare variants and a diversity of rare combinations, including unique ones were observed in two thirds of patients, expanding knowledge regarding European geographical trend in rare variants. Gene sequencing was necessary for genetic diagnosis. In the future the detection of rare genotypes may help to personalize preventive and therapeutic measures.

Financial support

None.

CRedit authorship contribution statement

S.A. Papiris: Conceptualization, Visualization, Funding acquisition, Formal analysis, Methodology, Writing – review & editing, Supervision. **M. Veith:** Formal analysis, Methodology, Writing – original draft. **A.I. Papaioannou:** Formal analysis, Methodology, Writing – original draft. **V. Apollonatos:** Funding acquisition, Methodology, Writing – review & editing. **I. Ferrarotti:** Methodology, Writing – review & editing. **S. Ottaviani:** Methodology, Writing – review & editing. **A. Tzouvelekis:** Funding acquisition, Methodology, Writing – review & editing. **V. Tzilas:** Funding acquisition, Methodology, Writing – review & editing. **N. Rovina:** Funding acquisition, Methodology, Writing – review & editing. **G.**

Stratakos: Funding acquisition, Methodology, Writing – review & editing. **I. Gerogianni:** Funding acquisition, Methodology, Writing – review & editing. **Z. Daniil:** Funding acquisition, Methodology, Writing – review & editing. **L. Kolilekas:** Funding acquisition, Methodology, Writing – review & editing. **K. Dimakou:** Funding acquisition, Methodology, Writing – review & editing. **G. Pitsidianakis:** Funding acquisition, Methodology, Writing – review & editing. **N. Tzanakis:** Funding acquisition, Methodology, Writing – review & editing. **S. Tryfon:** Funding acquisition, Methodology, Writing – review & editing. **F. Fragopoulos:** Funding acquisition, Methodology, Writing – review & editing. **E.M. Antonogiannaki:** Funding acquisition, Methodology, Writing – review & editing. **A. Lazaratou:** Funding acquisition, Methodology, Writing – review & editing. **E. Fouka:** Funding acquisition, Methodology, Writing – review & editing. **D. Papakosta:** Funding acquisition, Methodology, Writing – review & editing. **P. Emmanouil:** Funding acquisition, Methodology, Writing – review & editing. **N. Anagnostopoulos:** Funding acquisition, Methodology, Writing – review & editing. **T. Karampitsakos:** Funding acquisition, Methodology, Writing – review & editing. **K. Vlami:** Funding acquisition, Methodology, Writing – review & editing. **M. Kallieri:** Funding acquisition, Methodology, Writing – review & editing. **P. Lyberopoulos:** Funding acquisition, Methodology, Writing – review & editing. **S. Loukides:** Funding acquisition, Methodology, Writing – review & editing. **D. Bouros:** Funding acquisition, Methodology, Writing – review & editing. **A. Bush:** Methodology, Writing – review & editing. **M. Balduyck:** Formal analysis, Methodology, Writing – review & editing. **C. Lombard:** Formal analysis, Methodology, Writing – review & editing. **V. Cottin:** Formal analysis, Methodology, Writing – review & editing. **J.F. Mornex:** Formal analysis, Methodology, Writing – review & editing. **C.F. Vogelmeier:** Formal analysis, Methodology, Writing – review & editing. **T. Greulich:** Formal analysis, Methodology, Writing – review & editing. **E.D. Manali:** Conceptualization, Visualization, Funding acquisition, Formal analysis, Methodology, Writing – review & editing, Conceptualization, Visualization, Funding acquisition, Formal analysis, Supervision, Writing – review & editing.

Acknowledgements

The authors would like to acknowledge the contribution of the following collaborators in patient care: Aimilia Tsaroucha (2nd Pulmonary Department, Athens Chest Hospital "Sotiria", Athens Greece), Ilias C Papanikolaou (Department of Pulmonary Medicine, Corfu General Hospital), Michael Kitrou (Patras, Greece), Aggeliki Haritou (Ioannina, Greece), Zafeirios Sardelis (7th Pulmonary Department, Athens Chest Hospital "Sotiria", Athens Greece), Nikolaos Koulouris, Eleni Stagaki (1st Respiratory Medicine Department of the National, Kapodistrian University of Athens, Athens, Greece), Gerasimos Apollonatos (Peristeri, Athens, Greece), Maria Tsiamita (Department of Respiratory Medicine, General Hospital of Patras, University of Patras), Panagiota Loukopolou (Aigio, Greece), David Tsoukas (Florina, Greece), Stamatia Markou (Xanthi, Greece), Panagiotis Mavroudis (Hygeia Hospital, Athens), Ioanna Korbila, Galateia Verykoku, Maria Maniati, Konstantinos Kagouridis (2nd Pulmonary

Medicine Department, General University Hospital "Attikon", Medical School, National and Kapodistrian University of Athens), Konstantinos Douros, Smaragdi Fessatou, Ino Kanavaki, Vassiliki Papaevangelou (Third Department of Pediatrics "Attikon" University Hospital, National and Kapodistrian University of Athens School of Medicine Athens), Iraklis Tsangaris (Second Department of Critical Care Medicine, General University Hospital "Attikon", Medical School, National and Kapodistrian University of Athens) (all in Greece) and Julie Traclet (Service de pneumologie, centre national coordinateur de référence des maladies pulmonaires rares, Hôpital Louis Pradel, Hospices Civils de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, UMR754 INRA, IVPC, Lyon, France)

References

1. Stoller JK, Aboussouan LS. A review of $\alpha 1$ antitrypsin deficiency. *Am Respir Crit Care Med.* 2012;185(3):246–9.
2. Ferrarotti I, Thun GA, Zorzetto M, et al. Serum levels and genotype distribution of $\alpha 1$ -antitrypsin in the general population. *Thorax.* 2012;67(8):669–74.
3. Gadek JE, Klein HG, Holland PV, et al. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. *J Clin Invest.* 1981;68(5):1158–65.
4. Lomas DA, Parfrey H. Alpha1-antitrypsin deficiency. 4: molecular pathophysiology. *Thorax.* 2004;59(6):529–35.
5. Miravittles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in $\alpha 1$ -antitrypsin deficiency. *Eur Respir J.* 2017;50(5):1700610.
6. Fromme M, Schneider CV, Pereira V, et al. Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. *Gut.* 2022;71(2):415–23.
7. Franciosi AN, Ralph J, O'Farrell NJ, et al. Alpha-1 antitrypsin deficiency-associated panniculitis. *J Am Acad Dermatol.* 2022;87(4):825–32.
8. Seixas S, Marques PI. Known mutations at the cause of alpha-1 antitrypsin deficiency an updated overview of SERPINA1 variation spectrum. *Appl Clin Genet.* 2021;14:173–94.
9. Ferrarotti I, Thun GA, Probst-Hensch NM, et al. $\alpha 1$ -Antitrypsin level and pheno/genotypes. *Chest.* 2013;144(5):1732–3.
10. Hobbs BD, Silverman EK, Cho MH. Genetics and epidemiology. In: Strnad P, Brantly ML, Bals R, eds. *$\alpha 1$ -Antitrypsin Deficiency (ERS Monograph)*, Sheffield: European Respiratory Society; 2019:27–38.
11. Saltini C, Krotova K. Mechanisms of lung disease. In: Strnad P, Brantly ML, Bals R, eds. *$\alpha 1$ -Antitrypsin Deficiency (ERS Monograph)*, Sheffield: European Respiratory Society; 2019:52–6.
12. Lara B, Miravittles M. Spanish registry of patients with alpha-1 antitrypsin deficiency; comparison of the characteristics of PISZ and PIZZ individuals. *COPD.* 2015;12(1):27–31. Suppl.
13. Luisetti M, Ferrarotti I, Corda L, et al. Italian registry of patients with alpha-1 antitrypsin deficiency: general data and quality of life evaluation. *COPD.* 2015;12(1):52–7. Suppl.
14. McElvaney NG, Stoller JK, Buist AS, et al. Baseline characteristics of enrollees in the national heart, lung and blood institute registry of alpha 1-antitrypsin deficiency. *Alpha 1-Antitrypsin Deficiency Registry Study Group Chest.* 1997;111(2):394–403.
15. Koczulla R, Bittkowski N, Andress J, et al. The German registry of individuals with alpha-1-antitrypsin deficiency—a source for research on patient care. *Pneumologie.* 2008;62(11):655–8.

16. Gauvain C, Mornex JF, Pison C, et al. Health-related quality of life in patients with alpha-1 antitrypsin deficiency: the French experience. *COPD*. 2015;12(1):46–51. Suppl.
17. Veith M, Klemmer A, Anton I, et al. Diagnosing alpha-1-antitrypsin deficiency using a PCR/luminescence-based technology. *Int J Chron Obstruct Pulmon Dis*. 2019;14:2535–42.
18. Ottaviani S, Barzon V, Buxens A, et al. Molecular diagnosis of alpha-1-antitrypsin deficiency: a new method based on Luminex technology. *J Clin Lab Anal*. 2020;34(7):e23279.
19. Chapman KR, Burdon JG, Piitulainen E, et al. RAPID Trial Study Group. *Lancet*. 2015;386(9991):360–8.
20. Blanco I, Bueno P, Diego I, et al. Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update. *Int J Chron Obstruct Pulmon Dis*. 2017;12:561–9.
21. Blanco I, Diego I, Bueno P, et al. Prevalence of α 1-antitrypsin PiZZ genotypes in patients with COPD in Europe: a systematic review. *Eur Respir Rev*. 2020;29(127):200014.
22. Veeramah KR, Novembre J. Demographic events and evolutionary forces shaping European genetic diversity. *Cold Spring Harb Perspect Biol*. 2014;6(9):a008516.
23. Seixas S, Garcia O, Trovada MJ, et al. Patterns of haplotype diversity within the serpin gene cluster at 14q32.1: insights into the natural history of the alpha1-antitrypsin polymorphism. *Hum Genet*. 2001;108(1):20–30.
24. Blanco I, Bueno P, Diego I, et al. Alpha-1 antitrypsin Pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide. *Int J Chron Obstruct Pulmon Dis*. 2017;12:1683–94.
25. Silva D, Oliveira MJ, Guimarães M, et al. Alpha-1-antitrypsin (SERPINA1) mutation spectrum: three novel variants and haplotype characterization of rare deficiency alleles identified in Portugal. *Respir Med*. 2016;116:8–18.
26. Renoux C, Odou MF, Tosato G, et al. Description of 22 new alpha-1 antitrypsin genetic variants. *Orphanet J Rare Dis*. 2018;13(1):161.
27. Prins J, van der Meijden BB, Kraaijenhagen RJ, et al. Inherited chronic obstructive pulmonary disease: new selective-sequencing workup for alpha1-antitrypsin deficiency identifies 2 previously unidentified null alleles. *Clin Chem*. 2008;54(1):101–7.
28. Takahashi H, Nukiwa T, Satoh K, et al. Characterization of the gene and protein of the alpha 1-antitrypsin "deficiency" allele Mprocida. *J Biol Chem*. 1988;263(30):15528–34.
29. Nukiwa T, Takahashi H, Brantly M, et al. Alpha 1-Antitrypsin null Granite Falls, a non-expressing alpha 1-antitrypsin gene associated with a frameshift to stop mutation in a coding exon. *J Biol Chem*. 1987;262(25):11999–2004.
30. Jeppsson JO, Laurell CB, Nosslin B, et al. Catabolic rate of alpha1-antitrypsin of Pi types S, and MMalton and of asialylated M-protein in man. *Clin Sci Mol Med*. 1978;55(1):103–7.
31. Satoh K, Nukiwa T, Brantly M, et al. Emphysema associated with complete absence of alpha 1- antitrypsin in serum and the homozygous inheritance [corrected] of a stop codon in an alpha 1-antitrypsin-coding exon. *Am J Hum Genet*. 1988;42(1):77–83.
32. Giacomuzzi E, Laffranchi M, Berardelli R, et al. Real-world clinical applicability of pathogenicity predictors assessed on SERPINA1 mutations in alpha-1-antitrypsin deficiency. *Hum Mutat*. 2018;39(9):1203–13.
33. Curiel D, Brantly M, Curiel E, et al. Alpha 1-antitrypsin deficiency caused by the alpha 1-antitrypsin Nullmattawa gene. An insertion mutation rendering the alpha 1-antitrypsin gene incapable of producing alpha 1-antitrypsin. *J Clin Invest*. 1989;83(4):1144–52.
34. Poller W, Merklein F, Schneider-Rasp S, et al. Molecular characterisation of the defective alpha 1-antitrypsin alleles PI Mwurzburg (Pro369Ser), Mheerlen (Pro369Leu), and Q0lisbon (Thr68Ile). *Eur J Hum Genet*. 1999;7(3):321–31.
35. Hofker MH, Nukiwa T, van Paassen HM, et al. A Pro—Leu substitution in codon 369 of the alpha-1-antitrypsin deficiency variant PI MHeerlen. *Hum Genet*. 1989;81(3):264–8.
36. Hernández-Pérez JM, Ramos-Díaz R, Fumero-García S, Pérez JA. Molecular characterization of PI*Q0lapalma, a new alpha-1-antitrypsin null allele that combines two defective genetic variants. *Clin Genet*. 2017;91(6):927–8.
37. Matsunaga E, Shiokawa S, Nakamura H, et al. Molecular analysis of the gene of the alpha 1-antitrypsin deficiency variant, Mni-chinan. *Am J Hum Genet*. 1990;46(3):602–12.
38. Faber JP, Poller W, Weidinger S, et al. Identification and DNA sequence analysis of 15 new alpha 1-antitrypsin variants, including two PI*Q0 alleles and one deficient PI*M allele. *Am J Hum Genet*. 1994;55(6):1113–21.
39. Vaz Rodrigues L, Costa F, Marques P, et al. Severe α -1 antitrypsin deficiency caused by Q0(Ourém) allele: clinical features, haplotype characterization and history. *Clin Genet*. 2012;81(5):429–62.
40. Greulich T. Alpha-1-antitrypsin deficiency: disease management and learning from studies. *COPD*. 2017;14(sup1):S8–S11.
41. Balderacchi AM, Barzon V, Ottaviani S, et al. Comparison of different algorithms in laboratory diagnosis of alpha1-antitrypsin deficiency. *Clin Chem Lab Med*. 2021;59(8):1384–91.
42. Barzon V, Ottaviani S, Balderacchi AM, et al. Improving the laboratory diagnosis of M-like variants related to alpha1-antitrypsin deficiency. *Int J Mol Sci*. 2022;23(17):9859.
43. Tanash HA, Nilsson PM, Nilsson JA, et al. Clinical course and prognosis of never-smokers with severe alpha-1-antitrypsin deficiency (PiZZ). *Thorax*. 2008;63(12):1091–5.
44. Garver RI, Mornex JF, Nukiwa T, et al. Alpha1-antitrypsin deficiency and emphysema caused by homozygous inheritance of non-expressing alpha1-antitrypsin genes. *N Engl J Med*. 1986;314(12):762–6.
45. Ortega VE, Li X, O'Neal WK, et al. NHLBI subpopulations and intermediate outcomes measures in COPD study (SPIROMICS). The effects of rare SERPINA1 variants on lung function and emphysema in SPIROMICS. *Am J Respir Crit Care Med*. 2020;201(5):540–54.
46. Núñez A, Belmonte I, Miranda E, et al. Association between circulating alpha-1 antitrypsin polymers and lung and liver disease. *Respir Res*. 2021;22(1):244.
47. Hersh CP, Dahl M, Ly NP, et al. Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis. *Thorax*. 2004;59(10):843–9.
48. Ghosh AJ, Hobbs BD, Moll M. COPD Gene Investigators. Alpha-1 antitrypsin MZ heterozygosity is an endotype of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2022;205(3):313–23.
49. Ferrarotti I, Carroll TP, Ottaviani S, et al. Identification and characterization of eight novel SERPINA1 Null mutations. *Orphanet J Rare Dis*. 2014;9:172.
50. de Serres FJ, Blanco I. Prevalence of α 1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review. *Ther Adv Respir Dis*. 2012;6(5):277–95.